Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals

DUBLIN, Sept. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following a... Biopharmaceuticals, Generics, FDA, Litigation Allergan, NAMENDA, memantine, Lupin Pharmaceuticals
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news